0
USD
EUR USD GBP
+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Sustained Release Injectables Market by Application, Product Type, Polymer Type, Route Of Administration, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 182 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5533434
UP TO EUR$697USDGBP OFF until Dec 31st 2025
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Sustained Release Injectables Market grew from USD 2.29 billion in 2024 to USD 2.45 billion in 2025. It is expected to continue growing at a CAGR of 7.04%, reaching USD 3.45 billion by 2030.

Shaping the Future of Sustained Release Injectables

Sustained release injectables are revolutionizing how therapies are administered, offering prolonged drug delivery that enhances patient adherence and clinical outcomes. As chronic diseases and complex conditions become more prevalent, the ability to maintain therapeutic levels in the bloodstream over extended periods responds directly to patient needs and healthcare providers’ demands for efficiency. Industry stakeholders are increasingly focused on breakthrough formulations that reduce dosing frequency, minimize side effects, and expand access to advanced treatments beyond traditional hospital settings.

The rise of biologics and specialty drugs has spurred investment into innovative carriers that protect labile molecules while enabling controlled release. Advances in polymer science, microfabrication, and drug encapsulation techniques have driven down development timelines and fortified pipelines across therapeutic areas. Simultaneously, patient-centric care models underscore the importance of at-home administration and ambulatory solutions, accelerating demand for user-friendly delivery systems that balance safety with convenience.

This executive summary crystallizes the most significant developments shaping the sustained release injectables market. It highlights transformative landscape shifts, evaluates the cumulative effects of pending tariff adjustments, unpacks granular segmentation insights, surveys regional dynamics, profiles leading companies, and concludes with actionable recommendations. By distilling comprehensive research into clear strategic takeaways, decision-makers can steer their organizations toward sustainable growth and enduring innovation.

Pivotal Shifts Redining Treatment Delivery

The sustained release injectables sector is experiencing landmark shifts that are redefining treatment paradigms and business models alike. Polymer innovations are enabling bespoke release profiles, tailoring delivery to the pharmacokinetics of complex molecules. Simultaneously, digital health integrations such as smart pumps and connected platforms are setting new standards for dosage monitoring and real-time data analytics, empowering clinicians and patients with actionable insights.

Regulatory landscapes are also evolving to accommodate these hybrid drug-device products, streamlining approval pathways while maintaining rigorous safety and efficacy benchmarks. Accelerated review programs for orphan therapies and fast-track designations for breakthrough technologies are incentivizing development in areas like oncology and rare diseases. As personalized medicine moves to the forefront, developers are forging partnerships with diagnostic companies to co-create companion diagnostics that optimize patient selection and therapeutic outcomes.

Moreover, supply chain resilience has emerged as a strategic imperative. Companies are reengineering sourcing strategies to secure critical raw materials, from monomers and excipients to active pharmaceutical ingredients. In response, contract manufacturing organizations are expanding capacity for sterile injectable production, ensuring scalability and compliance with stringent quality standards. These combined forces are propelling the market into a new era of precision delivery and integrated care.

Navigating the Ripple Effects of 2025 Tariff Adjustments

Entering 2025, the cumulative impact of United States tariffs on pharmaceutical inputs has prompted a comprehensive reassessment of cost structures across the sustained release injectables value chain. Tariffs levied on polymer resins, specialized siloxanes, and other key raw materials have increased price pressures, compelling manufacturers to explore alternative suppliers and secure long-term contracts to mitigate volatility.

These adjustments have ripple effects on formulation budgets, driving R&D teams to prioritize cost-efficient materials without compromising release kinetics or biocompatibility. In some cases, companies are accelerating the adoption of domestic production for critical monomers and active compounds, aligning with reshoring initiatives to reduce dependency on higher-tariff regions. This shift not only addresses cost concerns but also enhances supply chain transparency and regulatory traceability.

Meanwhile, strategic procurement teams are negotiating tiered pricing agreements and leveraging economies of scale by consolidating volumes across multiple injectable platforms. Collaborative partnerships with contract development and manufacturing organizations are offering integrated sourcing solutions that stabilize input costs. Despite headwinds from tariff-induced inflation, these proactive measures are enabling stakeholders to maintain competitive positioning while preserving the high quality and performance that characterize sustained release formulations.

Unpacking the Market’s Core Segmentation Dynamics

A nuanced understanding of market segmentation reveals where sustained release injectables deliver the greatest value and where growth potential is most pronounced. In the realm of therapeutic applications, hormonal therapies remain a cornerstone of the market, driven by chronic conditions such as diabetes and contraceptive management. Oncology stands out for its dual focus on hematological malignancies and solid tumors, with breast cancer and lung cancer therapies charting particularly robust pipelines backed by demand for targeted, long-acting regimens. Pain management injectables are gaining traction as healthcare providers seek alternatives to oral opioids, while vaccine delivery platforms are expanding to support immunization programs with simplified dosing schedules.

On the product front, cartridges and implantable pumps are capitalizing on continuous infusion needs, especially in hospital and home healthcare settings where precision dosing is paramount. Pre-filled syringes deliver convenience and sterility for single-dose applications, while unfilled vials offer flexibility for compounding bespoke formulations. Material selection further refines product performance: biodegradable polymer systems such as polycaprolactone, polylactic acid and polylactic-co-glycolic acid are preferred for their predictable degradation profiles, whereas non-biodegradable options like polyethylene and polysiloxanes serve specialized uses requiring extended mechanical integrity.

The preferred routes of administration-epidural, intramuscular, intravitreal and subcutaneous-reflect the diversity of clinical needs, from localized pain relief to sustained ocular therapy. End users range from ambulatory surgical centers and clinics to home healthcare providers and large hospital networks, each demanding tailored delivery solutions that align with operational workflows. These intersecting segmentation dimensions guide investments, inform clinical trial design, and shape commercialization strategies across the injectables landscape.

Regional Horizons Driving Growth Momentum

Regional dynamics in the sustained release injectables market underscore divergent growth drivers and investment priorities. In the Americas, innovation is propelled by substantial healthcare expenditures and strong reimbursement frameworks. The United States leads in early adoption of advanced delivery platforms, underpinned by robust clinical trial activity and a favorable regulatory environment. Canada is following suit, leveraging cross-border research collaborations and growing home infusion services to expand access to long-acting therapies.

Across Europe, Middle East & Africa, a mosaic of healthcare systems is fostering both challenges and opportunities. Western Europe’s mature markets are characterized by rigorous price controls but high demand for differentiated delivery technologies. Emerging economies in the Middle East are investing in healthcare infrastructure and training programs to meet rising chronic disease burdens, while Africa’s growing focus on vaccine delivery logistics is enhancing the uptake of sustained release platforms.

Asia-Pacific is distinguished by its dynamic innovation ecosystems and sizable patient populations. Japan and South Korea are at the forefront of polymer research and precision medicine applications, while China’s market expansion is being fueled by government initiatives to localize production and improve rural healthcare access. Southeast Asian nations are increasingly integrating sustained release injectables into public health campaigns, capitalizing on simplified dosing regimens to reach underserved communities.

Leading Innovators Steering Industry Progress

Major industry players are intensifying efforts to consolidate their positions and accelerate innovation in sustained release injectables. Global pharmaceutical firms are forging strategic alliances with specialized device manufacturers to develop combination products that deliver both therapeutic payloads and real-time monitoring. These partnerships unlock synergies in formulation science and engineering, yielding integrated solutions tailored to chronic indications and complex biologics.

Contract development and manufacturing organizations are also rising to prominence, expanding sterile fill-finish facilities and investing in high-throughput polymer processing. Their capacity to manage scale-up challenges and regulatory compliance enables smaller biotech companies to bring novel sustained release therapies to market more efficiently. Meanwhile, technology innovators are pushing the boundaries of microfabrication, exploring nanostructured depots and bioresponsive release triggers that promise unprecedented control.

Venture capital and private equity firms are directing capital toward companies with differentiated pipeline assets and proprietary delivery platforms. Their backing accelerates clinical development and commercialization timelines, particularly in therapeutic areas with high unmet need. At the same time, health systems are piloting value-based contracting arrangements that reward long-acting therapeutics for improved adherence and reduced hospitalization rates. Collectively, these competitive dynamics are reshaping the landscape, driving consolidation, and elevating standards for quality and performance.

Strategic Imperatives to Elevate Market Position

Industry leaders must prioritize investment in advanced polymer research to refine release kinetics while optimizing cost structures. Allocating resources to biodegradable and non-biodegradable systems will enable customization of duration and mechanical properties, ensuring formulations meet the evolving demands of oncology, pain management and hormone therapy.

Strengthening supply chain resilience is equally critical. Formulation teams should secure dual-source agreements for key excipients and active molecules, while procurement professionals negotiate long-term partnerships with domestic suppliers to reduce tariff exposure. Embracing digital platforms for real-time inventory visibility will mitigate disruptions and support agile response protocols.

To capture diverse patient populations, companies should expand clinical development efforts across multiple routes of administration, from intramuscular injections to intravitreal delivery. Collaborations with healthcare providers and home care networks will facilitate patient education and adherence support programs, driving real-world effectiveness and enhancing payer confidence.

Finally, forging alliances with contract manufacturers and diagnostic firms can accelerate time to market for combination products. Integrating companion diagnostics into clinical protocols will unlock personalized treatment pathways, improve patient outcomes, and strengthen positioning in competitive therapeutic segments.

Rigorous Approach Underpinning Our Analysis

The analysis underpinning this report combines both primary and secondary research to deliver robust, actionable insights. Primary research involved in-depth interviews with industry executives, polymer scientists, formulation experts, regulatory advisors and contract manufacturing leaders. These discussions yielded qualitative insights into emerging technologies, commercialization challenges and competitive strategies.

Secondary research encompassed a comprehensive review of peer-reviewed journals, patent filings, regulatory guidelines and company disclosures. Proprietary databases were leveraged to analyze historical trends, market entry timelines and merger and acquisition activity. Data triangulation methods ensured consistency and accuracy by cross-referencing quantitative metrics with qualitative observations.

Regional analyses were informed by consultations with local market authorities and healthcare professionals, providing context on reimbursement frameworks, clinical adoption patterns and procurement practices. The segmentation framework was validated through iterative feedback loops with subject matter experts, ensuring that therapeutic, product, polymer, administration and end-user categories reflect current and future market realities.

Quality control measures included editorial reviews, methodological audits and scenario testing to assess sensitivity to tariff changes, regulatory shifts and technological breakthroughs. The result is a comprehensive, reliable resource designed to guide strategic planning and investment decisions across the sustained release injectables landscape.

Solidifying Insights for Informed Decision Making

The sustained release injectables market stands at a pivotal juncture, fueled by scientific breakthroughs, shifting regulatory paradigms and evolving patient expectations. By understanding the impact of tariff adjustments, segment-specific dynamics and regional growth drivers, stakeholders can navigate uncertainties and capitalize on emerging opportunities.

Key therapeutic areas such as oncology, hormonal therapies and pain management continue to attract significant investment, amplified by the need for personalized, long-acting solutions. Product innovations spanning cartridges, pumps, syringes and vials are enhancing procedural efficiencies and patient convenience. Material science advancements in both biodegradable and non-biodegradable polymers are refining release profiles to align with a spectrum of clinical applications.

Regional variations highlight the importance of tailored approaches: the Americas leverage strong reimbursement and R&D infrastructure, EMEA balances price controls with demand for premium technologies, and Asia-Pacific capitalizes on large patient bases and supportive government policies. Leading companies are navigating these nuances through strategic partnerships, capital investments and value-based contracting models.

By integrating these insights into strategic roadmaps, executives and investors can secure competitive positioning, drive sustainable growth and deliver transformative therapies to patients worldwide. This report serves as a foundation for informed decision making, enabling industry leaders to chart a course toward long-term success.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Application
    • Hormonal Therapies
    • Oncology
      • Hematological Malignancies
      • Solid Tumors
        • Breast Cancer
        • Lung Cancer
    • Pain Management
    • Vaccines
  • Product Type
    • Cartridges
    • Implantable Pumps
    • Pre-Filled Syringes
    • Unfilled Vials
  • Polymer Type
    • Biodegradable Polymers
      • PCL
      • PLA
      • PLGA
    • Non-Biodegradable Polymers
      • Polyethylene
      • Polysiloxanes
  • Route Of Administration
    • Epidural
    • Intramuscular
    • Intravitreal
    • Subcutaneous
  • End User
    • Ambulatory Surgical Centers
    • Clinics
    • Home Healthcare
    • Hospitals
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd
  • Sanofi S.A.
  • GlaxoSmithKline plc
  • AbbVie Inc.
  • Abbott Laboratories
  • Amgen Inc.
  • Baxter International Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Sustained Release Injectables Market, by Application
8.1. Introduction
8.2. Hormonal Therapies
8.3. Oncology
8.3.1. Hematological Malignancies
8.3.2. Solid Tumors
8.3.2.1. Breast Cancer
8.3.2.2. Lung Cancer
8.4. Pain Management
8.5. Vaccines
9. Sustained Release Injectables Market, by Product Type
9.1. Introduction
9.2. Cartridges
9.3. Implantable Pumps
9.4. Pre-Filled Syringes
9.5. Unfilled Vials
10. Sustained Release Injectables Market, by Polymer Type
10.1. Introduction
10.2. Biodegradable Polymers
10.2.1. PCL
10.2.2. PLA
10.2.3. PLGA
10.3. Non-Biodegradable Polymers
10.3.1. Polyethylene
10.3.2. Polysiloxanes
11. Sustained Release Injectables Market, by Route Of Administration
11.1. Introduction
11.2. Epidural
11.3. Intramuscular
11.4. Intravitreal
11.5. Subcutaneous
12. Sustained Release Injectables Market, by End User
12.1. Introduction
12.2. Ambulatory Surgical Centers
12.3. Clinics
12.4. Home Healthcare
12.5. Hospitals
13. Americas Sustained Release Injectables Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Sustained Release Injectables Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Sustained Release Injectables Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Johnson & Johnson
16.3.2. Novartis AG
16.3.3. Pfizer Inc.
16.3.4. F. Hoffmann-La Roche Ltd
16.3.5. Sanofi S.A.
16.3.6. GlaxoSmithKline plc
16.3.7. AbbVie Inc.
16.3.8. Abbott Laboratories
16.3.9. Amgen Inc.
16.3.10. Baxter International Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. SUSTAINED RELEASE INJECTABLES MARKET MULTI-CURRENCY
FIGURE 2. SUSTAINED RELEASE INJECTABLES MARKET MULTI-LANGUAGE
FIGURE 3. SUSTAINED RELEASE INJECTABLES MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. SUSTAINED RELEASE INJECTABLES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. SUSTAINED RELEASE INJECTABLES MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. SUSTAINED RELEASE INJECTABLES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY HORMONAL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY CARTRIDGES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY IMPLANTABLE PUMPS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRE-FILLED SYRINGES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY UNFILLED VIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PCL, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PLA, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PLGA, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYETHYLENE, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYSILOXANES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY EPIDURAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY INTRAVITREAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 62. CANADA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 63. CANADA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 64. CANADA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 65. CANADA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 66. CANADA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2030 (USD MILLION)
TABLE 67. CANADA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 68. CANADA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 69. CANADA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 70. CANADA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 71. MEXICO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 72. MEXICO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 73. MEXICO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 74. MEXICO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 75. MEXICO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2030 (USD MILLION)
TABLE 76. MEXICO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 77. MEXICO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 78. MEXICO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 79. MEXICO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 108. UNITED KINGDOM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 109. UNITED KINGDOM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 110. UNITED KINGDOM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 111. UNITED KINGDOM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 112. UNITED KINGDOM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2030 (USD MILLION)
TABLE 113. UNITED KINGDOM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 114. UNITED KINGDOM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 115. UNITED KINGDOM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 116. UNITED KINGDOM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. GERMANY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 118. GERMANY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 119. GERMANY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 120. GERMANY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 121. GERMANY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2030 (USD MILLION)
TABLE 122. GERMANY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 123. GERMANY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 124. GERMANY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 125. GERMANY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 126. FRANCE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 127. FRANCE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 128. FRANCE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 129. FRANCE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 130. FRANCE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2030 (USD MILLION)
TABLE 131. FRANCE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 132. FRANCE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 133. FRANCE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 134. FRANCE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 135. RUSSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 136. RUSSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 137. RUSSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 138. RUSSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 139. RUSSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2030 (USD MILLION)
TABLE 140. RUSSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 141. RUSSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 142. RUSSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 143. RUSSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 144. ITALY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 145. ITALY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 146. ITALY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 147. ITALY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 148. ITALY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2030 (USD MILLION)
TABLE 149. ITALY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 150. ITALY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 151. ITALY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 152. ITALY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 153. SPAIN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 154. SPAIN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 155. SPAIN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 156. SPAIN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 157. SPAIN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2030 (USD MILLION)
TABLE 158. SPAIN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 159. SPAIN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 160. SPAIN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 161. SPAIN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 162. UNITED ARAB EMIRATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 163. UNITED ARAB EMIRATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 164. UNITED ARAB EMIRATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 165. UNITED ARAB EMIRATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 166. UNITED ARAB EMIRATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2030 (USD MILLION)
TABLE 167. UNITED ARAB EMIRATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 168. UNITED ARAB EMIRATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 169. UNITED ARAB EMIRATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 170. UNITED ARAB EMIRATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 171. SAUDI ARABIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 172. SAUDI ARABIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 173. SAUDI ARABIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 174. SAUDI ARABIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 175. SAUDI ARABIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2030 (USD MILLION)
TABLE 176. SAUDI ARABIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 177. SAUDI ARABIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 178. SAUDI ARABIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 179. SAUDI ARABIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 180. SOUTH AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 181. SOUTH AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 182. SOUTH AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 183. SOUTH AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 184. SOUTH AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2030 (USD MILLION)
TABLE 185. SOUTH AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 186. SOUTH AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 187. SOUTH AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 188. SOUTH AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 189. DENMARK SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 190. DENMARK SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 191. DENMARK SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 192. DENMARK SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 193. DENMARK SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2030 (USD MILLION)
TABLE 194. DENMARK SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 195. DENMARK SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 196. DENMARK SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 197. DENMARK SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 198. NETHERLANDS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 199. NETHERLANDS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 200. NETHERLANDS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 201. NETHERLANDS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 204. NETHERLANDS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 205. NETHERLANDS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 206. NETHERLANDS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 207. QATAR SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 208. QATAR SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 209. QATAR SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 210. QATAR SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 211. QATAR SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2030 (USD MILLION)
TABLE 212. QATAR SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 213. QATAR SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 214. QATAR SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 215. QATAR SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 216. FINLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 217. FINLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 218. FINLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 219. FINLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 220. FINLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2030 (USD MILLION)
TABLE 221. FINLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 222. FINLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 223. FINLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 224. FINLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 225. SWEDEN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 226. SWEDEN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 227. SWEDEN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 228. SWEDEN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 229. SWEDEN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2030 (USD MILLION)
TABLE 230. SWEDEN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 231. SWEDEN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 232. SWEDEN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 233. SWEDEN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 234. NIGERIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 235. NIGERIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 236. NIGERIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 237. NIGERIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 238. NIGERIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2030 (USD MILLION)
TABLE 239. NIGERIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 240. NIGERIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 241. NIGERIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 242. NIGERIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 243. EGYPT SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 244. EGYPT SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 245. EGYPT SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 246. EGYPT SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 247. EGYPT SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2030 (USD MILLION)
TABLE 248. EGYPT SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 249. EGYPT SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 250. EGYPT SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 251. EGYPT SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 252. TURKEY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 253. TURKEY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 254. TURKEY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 255. TURKEY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 256. TURKEY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2030 (USD MILLION)
TABLE 257. TURKEY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 258. TURKEY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 259. TURKEY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 260. TURKEY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 261. ISRAEL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 262. ISRAEL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 263. ISRAEL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 264. ISRAEL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 265. ISRAEL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2030 (USD MILLION)
TABLE 266. ISRAEL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 267. ISRAEL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 268. ISRAEL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 269. ISRAEL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 270. NORWAY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 271. NORWAY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 272. NORWAY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 273. NORWAY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 274. NORWAY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2030 (USD MILLION)
TABLE 275. NORWAY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 276. NORWAY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 277. NORWAY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 278. NORWAY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 279. POLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 280. POLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 281. POLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 282. POLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 283. POLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2030 (USD MILLION)
TABLE 284. POLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 285. POLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 286. POLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 287. POLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 288. SWITZERLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 289. SWITZERLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 290. SWITZERLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 291. SWITZERLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 292. SWITZERLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2030 (USD MILLION)
TABLE 293. SWITZERLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 294. SWITZERLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 295. SWITZERLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 296. SWITZERLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 297. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 298. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 299. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 300. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 301. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMER TYPE, 2018-2030 (USD MILLION)
TABLE 302. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 303. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, 2018-2030 (USD MILLION)
TABLE 304. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 305. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END USER, 2018-2030

Companies Mentioned

The companies profiled in this Sustained Release Injectables market report include:
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd
  • Sanofi S.A.
  • GlaxoSmithKline plc
  • AbbVie Inc.
  • Abbott Laboratories
  • Amgen Inc.
  • Baxter International Inc.

Methodology

Table Information

This website uses cookies to ensure you get the best experience. Learn more